Arcturus Therapeutics Holdings Inc (ARCT) USD0.001
Arcturus Therapeutics Holdings Inc. is a clinical-stage messenger ribonucleic acid (mRNA) medicines company. The Company is engaged in the development of infectious disease vaccines, and significant opportunities within liver and respiratory rare diseases. The Company offers RNA medicines, RNA drug substance and nanoparticle-formulated drug products. The Company's technologies include Self-Transcribing and Replicating RNA (STARR) and lipid nanoparticle delivery system (LUNAR). The Company has developed the STARR technology platform which combines self-replicating RNA with LUNAR into a single solution. The products under developmental stage using STARR technology are ARCT-021 (LUNAR-COV19 Vaccine), LUNAR-FLU, ARCT-810 (LUNAR - ornithine transcarbamylase (OTC)) and ARCT-032 (LUNAR - cystic fibrosis (CF)). The Company has a pipeline of seven drug candidates in late-stage discovery and early stage development.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.